Antares Pharma to Report 2008 Second Quarter Financial Results on August 14, 2008

Antares Pharma, Inc. (AMEX:AIS), a specialty pharmaceutical company focused on improving pharmaceuticals through advanced drug delivery systems, today announced that it will report 2008 second quarter financial results on Thursday, August 14, 2008, before the open of the U.S. financial markets.

Jack E. Stover, Chief Executive Officer and Vice Chairman, and other members of Antares’ senior management will provide a company update and review 2008 second quarter results via webcast and conference call on Thursday, August 14, 2008, at 8:30 a.m. ET. The webcast of this call will be available from the investors/media section of the Company's web site, www.antarespharma.com, and will be archived for 30 days. Alternatively, callers may participate in the conference call by dialing 800.762.8779 (domestic) or 480.248.5081 (international). Participants should reference the Antares Pharma conference call. Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through Friday, August 29, 2008. To access the replay, callers should dial 800-406-7325 (domestic) or 303-590-3030 (international). The passcode is 3906819.

About Antares Pharma, Inc.

Antares Pharma is a specialized pharma product development company committed to improving pharmaceuticals through its patented drug delivery systems. Antares has three validated systems: the ATDTM Advanced Transdermal Gel Delivery system; subcutaneous injection technology platforms including VibexTM disposable pressure assisted auto injectors, ValeoTM/Vision® reusable needle-free injectors and disposable multi-use pen injectors and Easy TecTM oral disintegrating tablets (ODT). Two of the systems have generated FDA approved products. The Company’s products are engineered to improve safety and efficacy profiles by minimizing dosing and reducing side effects while enabling improved patient compliance. The Company’s lead product candidate, Anturol™, an oxybutynin ATD™ gel for the treatment of OAB (overactive bladder), is currently under evaluation in a pivotal Phase 3 trial. The Anturol™ trial is being conducted under an agreement reached with the U.S. Food and Drug Administration under its special protocol assessment, or SPA process.

Antares Pharma has corporate headquarters in Ewing, New Jersey, with subsidiaries performing research, development, manufacturing and product commercialization activities in Minneapolis, Minnesota and Basel, Switzerland.

Safe Harbor Statement

The 2008 second quarter results press and conference call will contain forward-looking statements, within the meaning of the "Safe Harbor" provisions of The Private Securities Litigation Reform Act of 1995, that involve significant risks and uncertainties, including those discussed in the release and others that can be found in the “Risk Factors” section of Antares’ Annual Report on Form 10-K for the year ended December 31, 2007, and in Antares’ periodic reports on Form 10-Q and other filings made with the Securities and Exchange Commission. Antares is providing the information contained in the press release and conference call as of the date of the release and does not undertake any obligation to update any forward-looking statements contained as a result of new information, future events or otherwise. The Company cautions investors not to place undue reliance on the forward-looking statements contained in the press release or the conference call. No forward-looking statement can be guaranteed and actual events and results may differ materially from those projected.